Cognition Therapeutics announces dosing of first patient in MAGNIFY study of CT1812

Article

CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.

Senior man organizing his medication into pill dispenser. Senior man taking pills from box. Healthcare and old age concept with medicines. Medicaments on table. (Adobe Stock / Przemek Klos)

CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema. (Adobe Stock / Przemek Klos)

Cognition Therapeutics announced it has dosed the first participant in the phase 2 Magnify study of CT1812, an oral therapy for the treatment of geographic atrophy (GA) secondary to dry age-related macular edema (AMD).

According to a press release from the company,1 the MAGNIFY study is a randomized, placebo-controlled trial expected to enroll approximately 246 adults diagnosed with dry AMD with measurable GA.

The company states that CT1812 will be given orally, opposed to the typical intravitreal injection many development-stage therapies use. It will be given once daily for 24 months to determine if it can slow disease progression, measured by changes in GA lesion size.

David R P Almeida, MD, MBA, PhD, a vitreoretinal surgeon and the president, CEO and director of clinical research at Erie Retinal Surgery enrolled the first patient in the Magnify trial and discussed the trial in a press release from Cognition.

“Given the complex nature of dry AMD, even with an approved complement inhibitor, it is likely that a significant proportion of patients may need and benefit from a drug that mitigates the disease progression through a unique mechanism of action,” said Almeida.

Lisa Ricciardi, MBA, president and CEO of Cognition discussed the unique, oral aspect of the Magnify trial in the release.

“Our research suggests that a σ-2 modulator, such as CT1812, has the potential to protect RPE cells from several of these key drivers, which may allow patients to retain their visual acuity for longer,” said Ricciardi.

CT1812 is an experimental small molecule sigma-2 (σ-2) receptor modulator designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.1

The company noted the σ-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with soluble beta amyloid (Aβ) oligomers, oxidative stress and other stressors. Cognition’s clinical program will assess if regulating these processes by modulating the σ-2 receptor with CT1812 can maintain homeostatic function.1

References:
  1. Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD. Cognition; July 11, 2023. Accessed July 11, 2023. https://ir.cogrx.com/news-releases/news-release-details/cognition-therapeutics-announces-dosing-first-patient-magnify
Recent Videos
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
© 2025 MJH Life Sciences

All rights reserved.